This protocol is a dose escalation study of Ad - hCMV - TK and Ad - hCMV - Flt3L infused at the time of surgical resection followed by
systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy.
Not exact matches
The US Food and Drug
Administration (FDA) recently approved the
oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require
systemic therapy and have had at least one prior anti-CD20 therapy.
When a remedy is needed for more
systemic use but
oral administration is not an option, a wet remedy or pre-prepared cream can be applied to pulse points of the body, such as behind the knee or the inside of the wrist.